# US 2010/0144842 A1 · RNA Interference Mediated Inhibition of NOGO and NOGO Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0144842 A1
- Document ID: US20100144842A1
- Status: Published application
- Kind: A1
- Application number: 12/693,900
- Filed: 2010-01-26
- Published: 2010-06-10
- Earliest claimed: 2002-02-20
- Assignees: Sirna Therapeutics, Inc.
- Inventors: James McSwiggen; Leonid Beigelman
- Web page: https://patentgrep.com/patent/US20100144842A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61P 35/00: Antineoplastic agents
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/33: of the base
- C12N 2320/51: modulating the chemical stability, e.g. nuclease-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This invention relates to compounds, compositions, and methods useful for modulating NOGO and/or NOGO receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of NOGO and/or NOGO receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of NOGO and/or NOGO receptor genes, such as NOGO-A, NOGO-B, NOGO-C, NOGO-66 receptor, NI-35, NI-220, NI-250, myelin-associated glycoprotein, tenascin-R, and NG-2

## Claims

### Claim 1

A chemically modified nucleic acid molecule, wherein:
(a) the nucleic acid molecule comprises a sense strand and a separate antisense strand, each strand having one or more pyrimidine nucleotides and one or more purine nucleotides;
(b) each strand of the nucleic acid molecule is independently 18 to 27 nucleotides in length;
(c) an 18 to 27 nucleotide sequence of the antisense strand is complementary to a human NOGO receptor RNA sequence comprising SEQ ID NO:325;
(d) the sense strand has a Stab 7 stabilization chemistry configuration, wherein each pyrimidine nucleotide has a 2′-fluoro modification, each purine nucleotide has a 2′-deoxy modification and both the 5′- and 3′-ends have a terminal cap moiety;
(e) the antisense strand has a Stab 11 stabilization chemistry configuration, wherein each pyrimidine nucleotide has a 2′-fluoro modification, each purine nucleotide has a 2′-deoxy modification and the antisense strand has a phosphorothioate internucleotide linkage at the 3′-end; and
(f) wherein the nucleic acid molecule mediates RNA interference.

### Claim at position 2

2-14. (canceled)

### Claim 15 (depends on 1)

The nucleic acid molecule of claim 1, wherein the terminal cap moiety is an inverted deoxy abasic moiety.

### Claim 16 (depends on 1)

The nucleic acid molecule of claim 1, wherein said nucleic acid molecule includes two or more phosphorothioate internucleotide linkages.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The nucleic acid molecule of claim 1, wherein the 5′-end of the antisense strand includes a terminal phosphate group.

### Claim 19 (depends on 1)

The nucleic acid molecule of claim 1, wherein the sense strand, the antisense strand, or both the sense strand and the antisense strand include a 3′-overhang.

### Claim 20 (depends on 1)

A composition comprising the nucleic acid molecule of claim 1, in a pharmaceutically acceptable carrier or diluent.

### Claim 21 (depends on 19)

The nucleic acid molecule of claim 19, wherein both the sense and the antisense strand include a 3′-overhang.

### Claim 22 (depends on 19)

The nucleic acid molecule of claim 19, wherein the 3′-overhang comprises 1-4 nucleotides in length.

### Claim 23 (depends on 19)

The nucleic acid molecule of claim 19, wherein the 3′-overhang comprises thymidine residues.

### Claim 24 (depends on 19)

The nucleic acid molecule of claim 19, wherein the overhang comprises ribonucleotides.

### Claim 25 (depends on 19)

The nucleic acid molecule of claim 19 wherein the overhang comprises ribonucleotides that are chemically modified at a nucleic acid sugar, base, or backbone.

### Claim 26 (depends on 1)

The nucleic acid molecule of claim 1, comprising one or more blunt ends.
